The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 40 | — | 20.1x | Near average | |
Growth | 22 | 1.9% | 5.6% | Below average | |
Quality | 32 | -107.8% | 7.6% | Below average | |
Safety | 38 | -0.3x | 0.4x | Near average | |
Capital Return | 15 | — | 2.19% | Below average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
ARS Pharmaceuticals, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy ARS Pharmaceuticals, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
The data shows remarkable stability in analyst sentiment for SPRY, with the average price target holding steady at 25.5 dollars, unchanged over the past 30 days. This stability reflects high confidence from the three analysts covering the stock, with very minimal dispersion in estimates (range between 25 and 26 dollars), indicating a strong consensus on the expected fair value despite the significant gap between the current price (8.75) and the target.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.